at the BIO CEO & Investor Conference, to be held at the Waldorf-Astoria
in New York City. A live audio webcast of this presentation will be
available on the investor relations section of the company's website at
http://www.Replidyne.com. The webcast will be archived and available on
Replidyne's website after the event for a period of 30 days.
-- At the same conference, Replidyne's Chief Commercial Officer Peter
Letendre, Pharm.D. will participate on antibiotics panel "Super Drugs
Against Super Bugs" on Wednesday, February 13, 2008 at 9:30 A.M.
About Replidyne, Inc.
Replidyne is a biopharmaceutical company focused on discovering, developing, in-licensing and commercializing innovative anti-infective products. Replidyne's lead product, faropenem medoxomil, is a novel oral community antibiotic, expected to be appropriate for use as a first-line antibiotic for treatment of respiratory and skin infections in adult and pediatric patients. Replidyne's investigational antibacterial agent REP3123 targets Gram-positive C. difficile bacteria and C. difficile-associated disease (CDAD). Replidyne is pursuing the development of other novel anti-infective programs based on its DNA replication inhibition technology and its in-house discovery research.
This press release contains plans, intentions, objectives, estimates
and expectations that constitute forward-looking statements about
Replidyne, Inc. that involve significant risks and uncertainties. Actual
results could differ materially from those discussed due to a number of
factors including, the success and timing of pre-clinical studies and
clinical trials; the Company's ability to obtain a new partner for
faropenem on acceptable terms; the Company's ability to obtain and maintain
regulatory approval of product candidates and the labeling under any
|SOURCE Replidyne, Inc.|
Copyright©2008 PR Newswire.
All rights reserved